vTv Therapeutics Inc (NASDAQ:VTVT) Expected to Announce Quarterly Sales of $1.69 Million

Analysts expect that vTv Therapeutics Inc (NASDAQ:VTVT) will announce sales of $1.69 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for vTv Therapeutics’ earnings, with the lowest sales estimate coming in at $880,000.00 and the highest estimate coming in at $2.50 million. vTv Therapeutics reported sales of $3.38 million during the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The business is expected to report its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that vTv Therapeutics will report full year sales of $6.16 million for the current financial year, with estimates ranging from $4.62 million to $7.70 million. For the next year, analysts expect that the business will report sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million.

VTVT has been the subject of several recent analyst reports. Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Northland Securities reiterated a “buy” rating and set a $8.00 price target on shares of vTv Therapeutics in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 16th. Finally, ValuEngine cut vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th.

Shares of vTv Therapeutics stock traded up $0.09 during mid-day trading on Friday, hitting $1.47. 4,846 shares of the stock were exchanged, compared to its average volume of 227,725. vTv Therapeutics has a 12 month low of $0.68 and a 12 month high of $6.09. The company has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $1.56. The company has a market capitalization of $73.62 million, a P/E ratio of -2.13 and a beta of -3.64.

In related news, major shareholder Ronald O. Perelman acquired 50,000 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average price of $1.38 per share, with a total value of $69,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman acquired 150,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was bought at an average cost of $1.31 per share, with a total value of $196,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 4,442,424 shares of company stock valued at $7,265,500. Company insiders own 1.70% of the company’s stock.

A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. grew its position in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,031 shares of the biotechnology company’s stock after purchasing an additional 13,305 shares during the period. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 as of its most recent SEC filing. 1.64% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Further Reading: What are the reasons investors use put options?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.